



Themed Discussion-05

Tuesday, February 24, 2026

405 - Bispecific Biologics That Activate Latent HIV-1 Ex Vivo and In Vivo

David D. Ho

Aaron Diamond AIDS Research Center, New York, NY, USA


Financial Relationships:

Dr Ho reported Institution: Consulting or advisor fee with ImmunoCure and ProtaBody, and Institution: Research agreement with Merck & Co., Inc.




CROI 2026

Specificity of lymphocyte activation (CD69) by N803, T4IL15 & T4IL15Δ



	IL15/Rα	IL15/Rα	IL15/Rα	iMab	IL15Δ/Rα	iMab
	IL15dsFc (N803-like)		T4IL15		T4IL15Δ	
CD4	Naive	+/-	+/-		-	
	Memory	++	++++		+++	
CD8	Naive	+	+		-	
	Memory	+	+		-	
NK		+	+		-	




Ex vivo reactivation of latent HIV-1 in PBMCs from PLWH on suppressive ART and blunting of the resultant virus release by co-administration of a pyroptotic agent Pyr01



HIV-1 reactivation in infected humanized mice on suppressive ART occurs frequently when given T4IL15 or T4IL15Δ



Activation of HIV-1 latent reservoir in individual humanized mice



Conclusions

T4IL15 Δ can activate latent HIV-1 ex vivo and in vivo at high frequency

We are now pursuing the use of this latency reversal agent in combination with even better pyroptotic small molecules in HIV-1 cure studies